Identification of Aberrantly Methylated Differentially Expressed Genes to Distinguish High- vs. Low-Risk Retinoblastoma |
Children’s Hospital Los Angeles / Jesse Berry, MD |
Reach Grants |
2023 |
California |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |
Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG |
The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD |
Reach Grants |
2022 |
Michigan |
IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas |
Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD |
Reach Grants |
2021 |
New York |
DFMO Synergy with Chemo-immunotherapy to Eradicate MYC-Driven Neuroblastoma |
Children’s Hospital of Philadelphia / Michael Hogarty, MD |
Reach Grants |
2016 |
Pennsylvania |
Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma
|
The Johns Hopkins University School of Medicine / David Loeb, MD, PhD |
Reach Grants |
2013 |
Maryland |
Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD |
Reach Grants |
2017 |
New York |
Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition
|
Children’s Hospital of Philadelphia / Yael Mossé, MD |
Reach Grants |
2013 |
Pennsylvania |
Targeting a Novel Epigenetic Signature in Diffuse Intrinsic Pontine Gliomas |
New York University School of Medicine / Danny Reinberg, PhD |
Reach Grants |
2019 |
New York |